Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Recurrent Pyogenic Cholangitis Treatment & Management

  • Author: Praveen K Roy, MD, AGAF; Chief Editor: Julian Katz, MD  more...
 
Updated: Jul 24, 2015
 

Approach Considerations

Patients must be treated with a multidisciplinary approach by multiple subspecialists; therefore, referral to a tertiary center is prudent. Preferably, care should be rendered by individuals who are regional experts in interventional endoscopy, radiology, and hepatobiliary surgery.

Medical care generally involves parenteral antibiotics, avoidance, and/or prompt recognition and treatment of complications. Patients who are malnourished require nutritional rehabilitation.

A biliary drainage procedure is necessary to achieve resolution of the initial infection and to pursue the ultimate goal of preventing further attacks of recurrent cholangitis. The choice of biliary drainage procedure should hinge on patient presentation, comorbidities, cholangiographic findings, and local expertise. To prevent further attacks of cholangitis, these patients are best treated using a multidisciplinary approach of interventional gastroenterology, interventional radiology, and gastrointestinal surgery. Referral to an institution with considerable experience in the management of complex biliary disease is prudent.

Initial biliary decompression is achieved at ERCP, which also allows for the delineation of the biliary tree, an essential step in the planning of the definitive decompressive procedure. Sphincterotomy, stricture dilatation, and placement of a biliary endoprosthesis (stent) often are necessary to achieve biliary decompression and, when appropriate, to alleviate stasis or luminal compromise in the biliary tree, thus preventing further episodes of pyogenic cholangitis. The results of endotherapy appear to be durable in well-selected patients.

Following hospital discharge, careful follow-up with meticulous imaging studies and serial liver function tests is prudent. These studies often provide the first clue that full clearance of the bile ducts has not been achieved or that stone formation has recurred.

Little or no data are available on prevention; however, an overall improvement in living standards appears to parallel a decline in incidence of this disease.

Next

Surgical Care

In some patients, initial medical management may fail and patients may require emergency surgery. These patients often have acute suppurative cholecystitis and require emergent cholecystectomy or percutaneous cholecystotomy (as a temporizing measure). Definitive surgery is directed toward optimizing biliary outflow and is determined by the anatomical extent of involvement. For information on follow-up care, see Further Inpatient Care.

Surgery is necessary in patients who have concomitant cholelithiasis or complex hepatolithiasis.[8, 9] The surgical approach is based on the appearance at cholangiography and on axial imaging or MRCP. Note the following:

  • The usual surgical approach includes the following: (1) cholecystectomy, (2) intraoperative stone clearance by ERCP, (3) percutaneous cholangiography, (4) lithotripsy (ie, mechanical, laser, electrohydraulic), and (5) a definitive biliary drainage procedure.
  • Definitive drainage procedures include operative sphincteroplasty and appropriate biliodigestive bypass.
  • Many surgeons favor performing a Roux-en-Y choledochojejunostomy. Access to the Roux limb for reintervention (if necessary) is achieved percutaneously or endoscopically.

In a retrospective analysis, Lee et al looked at the outcomes of 85 patients who underwent any of the following treatments for recurrent pyogenic cholangitis: hepatectomy (65.9%); hepatectomy combined with drainage (9.4%); drainage alone (14.1%), and percutaneous choledochoscopy (10.6%).[10]

No operative moralities occurred, although 40% of patients suffered complications, half of them involving wound infections. Over a median follow-up period of 45.4 months, patients experienced a residual stone (21.2%), stone recurrence (16.5%), and biliary sepsis recurrence (21.2%), with the greatest incidence of these being in patients who had undergone drainage alone or had been treated with percutaneous choledochoscopy.[10]

In patients who had undergone hepatectomy alone or in combination with drainage, over a median follow-up period of 42.7 months, the frequency of residual stone was 15.6%, stone recurrence was 7.8%, and biliary sepsis recurrence was 9.4%.[10] Based on the study results, the authors recommended that hepatectomy should be considered the treatment of choice for suitable patients with recurrent pyogenic cholangitis.[10]

Previous
Next

Consultations

Optimal management of these cases usually requires many consultants who must work in a synergistic fashion to achieve the desired optimal outcome. Potential consultants include interventional gastroenterologists, interventional radiologists, and hepatobiliary surgeons.

Infectious disease experts often help guide the investigation for and the treatment of concurrent helminthic infection.

In the minority of patients who present with the complication of cholangiocarcinoma, consultation with an oncology specialist is prudent.

Previous
 
 
Contributor Information and Disclosures
Author

Praveen K Roy, MD, AGAF Chief of Gastroenterology, Presbyterian Hospital; Medical Director of Endoscopy, Presbyterian Medical Group; Adjunct Associate Research Scientist, Lovelace Respiratory Research Institute

Praveen K Roy, MD, AGAF is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Coauthor(s)

Rajan Kanth, MD Hospitalist, Ministry Saint Joseph’s Hospital

Rajan Kanth, MD is a member of the following medical societies: American College of Physicians, Society of Hospital Medicine, Nepal Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Additional Contributors

Anil Minocha, MD, FACP, FACG, AGAF, CPNSS Professor of Medicine, Director of Digestive Diseases, Medical Director of Nutrition Support, Medical Director of Gastrointestinal Endoscopy, Internal Medicine Department, University of Mississippi Medical Center; Clinical Professor, University of Mississippi School of Pharmacy

Anil Minocha, MD, FACP, FACG, AGAF, CPNSS is a member of the following medical societies: American Academy of Clinical Toxicology, American Society for Gastrointestinal Endoscopy, American Federation for Clinical Research, American Association for the Study of Liver Diseases, American College of Forensic Examiners Institute, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Patrick I Okolo III, MD, MPH, and previous coauthor Sam Yoselevitz, MD, to the development and writing of this article.

References
  1. Koklu S, Akkus MA, Tas A, et al. Recurrent pyogenic cholangitis in a case with congenital biliary anomaly. Ann Hepatol. 2012 Mar-Apr. 11(2):268-71. [Medline].

  2. Jeyarajah DR. Recurrent pyogenic cholangitis. Curr Treat Options Gastroenterol. 2004 Apr. 7(2):91-98. [Medline].

  3. Bass N. Sclerosing Cholangitis and Recurrent Pyogenic Cholangitis. Feldman M, Scharschmidt B, Slesinger M, eds. Gastrointestinal and Liver Disease. Philadelphia, Pa: WB Saunders; 1993. Vol 1: 1006-25.

  4. Chan FL, Chan JK, Leong LL. Modern imaging in the evaluation of hepatolithiasis. Hepatogastroenterology. 1997 Mar-Apr. 44(14):358-69. [Medline].

  5. Jain M, Agarwal A. MRCP findings in recurrent pyogenic cholangitis. Eur J Radiol. 2008 Apr. 66(1):79-83. [Medline].

  6. Heffernan EJ, Geoghegan T, Munk PL, Ho SG, Harris AC. Recurrent pyogenic cholangitis: from imaging to intervention. AJR Am J Roentgenol. 2009 Jan. 192(1):W28-35. [Medline]. [Full Text].

  7. Eun HW, Kim JH, Hong SS, Kim YJ. Malignant versus benign hepatic masses in patients with recurrent pyogenic cholangitis: MR differential diagnosis. Abdom Imaging. 2012 Oct. 37(5):767-74. [Medline].

  8. Al-Sukhni W, Gallinger S, Pratzer A, Wei A, Ho CS, Kortan P, et al. Recurrent pyogenic cholangitis with hepatolithiasis--the role of surgical therapy in North America. J Gastrointest Surg. 2008 Mar. 12(3):496-503. [Medline].

  9. Tsui WM, Chan YK, Wong CT, Lo YF, Yeung YW, Lee YW. Hepatolithiasis and the syndrome of recurrent pyogenic cholangitis: clinical, radiologic, and pathologic features. Semin Liver Dis. 2011 Feb. 31(1):33-48. [Medline].

  10. Lee KF, Chong CN, Ng D, et al. Outcome of surgical treatment for recurrent pyogenic cholangitis: a single-centre study. HPB (Oxford). 2009. 11(1):75-80. [Medline]. [Full Text].

  11. Afagh A, Pancu D. Radiologic findings in recurrent pyogenic cholangitis. J Emerg Med. 2004 Apr. 26(3):343-6. [Medline].

  12. American College of Surgeons. Surgical Education and Self-assessment Program (SESAP). Recurrent pyogenic cholangitis. Can J Surg. 2004 Apr. 47(2):121. [Medline].

  13. Carmona RH, Crass RA, Lim RC Jr, Trunkey DD. Oriental cholangitis. Am J Surg. 1984 Jul. 148(1):117-24. [Medline].

  14. Chen MF, Jan YY, Wang CS, et al. A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer. 1993 Apr 15. 71(8):2461-5. [Medline].

  15. Chen PH, Lo HW, Wang CS, et al. Cholangiocarcinoma in hepatolithiasis. J Clin Gastroenterol. 1984 Dec. 6(6):539-47. [Medline].

  16. Cheng YF, Lee TY, Sheen-Chen SM, Huang TL, Chen TY. Treatment of complicated hepatolithiasis with intrahepatic biliary stricture by ductal dilatation and stenting: long-term results. World J Surg. 2000 Jun. 24(6):712-6. [Medline].

  17. Chijiiwa K, Yamashita H, Yoshida J, Kuroki S, Tanaka M. Current management and long-term prognosis of hepatolithiasis. Arch Surg. 1995 Feb. 130(2):194-7. [Medline].

  18. Cosenza CA, Durazo F, Stain SC, Jabbour N, Selby RR. Current management of recurrent pyogenic cholangitis. Am Surg. 1999 Oct. 65(10):939-43. [Medline].

  19. Digby KH. Common-duct stones of liver origin. Br J Surg. 1930. 17:578-91.

  20. Koga A, Ichimiya H, Yamaguchi K, Miyazaki K, Nakayama F. Hepatolithiasis associated with cholangiocarcinoma. Possible etiologic significance. Cancer. 1985 Jun 15. 55(12):2826-9. [Medline].

  21. Lam SK. A study of endoscopic sphincterotomy in recurrent pyogenic cholangitis. Br J Surg. 1984 Apr. 71(4):262-6. [Medline].

  22. Lee SK, Seo DW, Myung SJ, et al. Percutaneous transhepatic cholangioscopic treatment for hepatolithiasis: an evaluation of long-term results and risk factors for recurrence. Gastrointest Endosc. 2001 Mar. 53(3):318-23. [Medline].

  23. Lee Y, Lee BH, Park JH, Suh CH. Balloon dilatation of intrahepatic biliary strictures for percutaneous extraction of residual intrahepatic stones. Cardiovasc Intervent Radiol. 1991 Mar-Apr. 14(2):102-5. [Medline].

  24. Lim JH. Oriental cholangiohepatitis: pathologic, clinical, and radiologic features. AJR Am J Roentgenol. 1991 Jul. 157(1):1-8. [Medline].

  25. Min HK. Clonorchis sinensis: pathogenesis and clinical features of infection. Arzneimittelforschung. 1984. 34(9B):1151-3. [Medline].

  26. Nakanuma Y, Terada T, Tanaka Y, Ohta G. Are hepatolithiasis and cholangiocarcinoma aetiologically related? A morphological study of 12 cases of hepatolithiasis associated with cholangiocarcinoma. Virchows Arch A Pathol Anat Histopathol. 1985. 406(1):45-58. [Medline].

  27. Ng WT. Pathogenesis of acute cholecystitis and recurrent pyogenic cholangitis. Surg Laparosc Endosc Percutan Tech. 2004 Aug. 14(4):240-1. [Medline].

  28. Saing H, Chan KL, Mya GH, Cheng W, Fan ST, Chan FL. Cutaneous stoma in the roux limb of hepaticojejunostomy (hepaticocutaneous jejunostomy): useful access for intrahepatic stone extraction. J Pediatr Surg. 1996 Feb. 31(2):247-50. [Medline].

  29. Schulman A. Intrahepatic biliary stones: imaging features and a possible relationship with ascaris lumbricoides. Clin Radiol. 1993 May. 47(5):325-32. [Medline].

  30. Sheen-Chen S, Chen W, Eng H, et al. Bacteriology and antimicrobial choice in hepatolithiasis. Am J Infect Control. 2000 Aug. 28(4):298-301. [Medline].

  31. Sperling RM, Koch J, Sandhu JS, Cello JP. Recurrent pyogenic cholangitis in Asian immigrants to the United States: natural history and role of therapeutic ERCP. Dig Dis Sci. 1997 Apr. 42(4):865-71. [Medline].

  32. Stain SC, Incarbone R, Guthrie CR, et al. Surgical treatment of recurrent pyogenic cholangitis. Arch Surg. 1995 May. 130(5):527-32; discussion 532-3. [Medline].

  33. Tanaka M, Ikeda S, Ogawa Y, et al. Divergent effects of endoscopic sphincterotomy on the long-term outcome of hepatolithiasis. Gastrointest Endosc. 1996 Jan. 43(1):33-7. [Medline].

  34. Tang CN, Tai CK, Ha JP, Siu WT, Tsui KK, Li MK. Laparoscopy versus open left lateral segmentectomy for recurrent pyogenic cholangitis. Surg Endosc. 2005 Sep. 19(9):1232-6. [Medline].

  35. Tang CN, Tai CK, Siu WT, Ha JP, Tsui KK, Li MK. Laparoscopic treatment of recurrent pyogenic cholangitis. J Hepatobiliary Pancreat Surg. 2005. 12(3):243-8. [Medline].

  36. Wong WT, Teoh-Chan CH, Huang CT, Cheng FC, Ong GB. The bacteriology of recurrent pyogenic cholangitis and associated diseases. J Hyg (Lond). 1981 Dec. 87(3):407-12. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.